CDNA: מכפיל P/S CareDx Health

CareDx, Inc (CDNA) is optimizing costs by outsourcing a portion of its laboratory processes and logistics to third-party contractors. The price-to-sales ratio serves as an indicator of market confidence, with the value of 8.40 acting as the target level. The business relies on the diversification of tests for various organs and software, while organic growth is driven by deep partnerships with clinics without the acquisition of third-party assets.

Assessing the investment risks of CareDx, Inc (CDNA) requires an analysis of the market capitalization to annual revenue ratio, which allows for the identification of asset overvaluation through deviations from average values. The efficiency of this model, including the costs of express delivery for biological samples, is reflected in the price-to-sales ratio, measuring how much an investor pays per unit of revenue, which helps determine a safe entry point and the probability of a price correction.